Search results
Showing 1546 to 1560 of 2008 results for nice guidelines
NICE technology appraisal and highly specialised technologies guidance: the manual (PMG36)
This guide describes the methods and processes, including expected timescales, that NICE follows when carrying out health technology evaluations. The methods and processes are designed to produce robust guidance for the NHS in an open, transparent and timely way, with appropriate contribution from stakeholders. Organisations invited to contribute to health technology evaluation development should read this manual in conjunction with the NICE health technology evaluation topic selection: the manual. All documents are available on the NICE website
NICE has developed a medtech innovation briefing (MIB) on Natural Cycles for monitoring fertility .
This guidance has been withdrawn as the use of this procedure is now covered in the NICE guideline on heavy menstrual bleeding (CG44). NICE has no plans to carry out further assessment of this procedure under the Interventional Procedures Programme.
This guidance has been replaced by NICE technology appraisal guidance 98 [Replaced by NICE guideline NG87].
Evidence-based recommendations on colistimethate sodium (Colobreathe) and tobramycin (TOBI Podhaler) dry powders for inhalation for treating pseudomonas lung infection in cystic fibrosis in people of 6 years and over.
Topical antimicrobial dressings for locally infected leg ulcers: late-stage assessment (HTG751)
Late stage assessment (LSA) guidance on topical antimicrobial dressings for locally infected leg ulcers.
View recommendations for HTG751Show all sections
Transobturator foramen procedures for stress urinary incontinence (IPG107)
The National Institute for Health and Clinical Excellence (NICE) issued full guidance to the NHS in England, Wales, Scotland and Northern Ireland on transobturator foramen procedures for stress incontinence in January 2005. This guidance has been withdrawn as the use of this procedure is now covered in NICE guideline CG40. NICE has no plans to carry out further assessment of this procedure under the Interventional Procedures Programme.
Early value assessment (EVA) guidance on artificial intelligence (AI) technologies for assessing and triaging skin lesions referred to the urgent suspected skin cancer pathway.
Guidance on the use of gemcitabine for the treatment of pancreatic cancer (TA25)
This guidance has been replaced by NICE guideline NG85.
This guidance has been replaced by NICE guideline CG74.
This guidance has been replaced by NICE guideline CG43.
The clinical effectiveness and cost effectiveness of sibutramine for obesity (TA31)
This guidance has been replaced by NICE guideline CG43.
This guidance has been replaced by NICE guideline CG81.
The clinical effectiveness and cost effectiveness of new drugs for bipolar disorder (TA66)
This guidance has been updated and replaced NICE guideline CG38.
This guidance has been updated and replaced by NICE guideline CG175.